ARS Pharmaceuticals, Inc. (SPRY) Balance Sheet
As of 2026-06-30 (10-Q), ARS Pharmaceuticals, Inc. (SPRY) reported total assets of $249.5M, total liabilities of $237.0M and shareholders' equity of $12.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $8.2M. Long-term debt: $96.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SPRYARS Pharmaceuticals, Inc.Follow SPRY — free
—
Price chart with a free account
- Market cap
- 400.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 60.1 | 210.5 | 71.0 | 50.8 | 41.3 | 8.2 | |
| Short-term investments | 0.0 | 63.9 | 157.4 | 263.2 | 203.7 | 135.7 | |
| Receivables | — | — | 0.0 | 8.2 | 25.3 | 46.8 | |
| Inventory | — | — | 0.0 | 10.5 | 31.4 | 30.7 | |
| Current assets | 60.7 | 277.7 | 231.7 | 334.3 | 284.9 | 211.5 | |
| Total assets | 61.4 | 281.4 | 233.2 | 351.2 | 327.7 | 249.5 | |
| Current liabilities | 8.2 | 5.4 | 2.4 | 23.4 | 39.1 | 60.9 | |
| Long-term debt | 4.9 | 0.0 | — | 0.0 | 96.4 | 96.7 | |
| Total liabilities | 16.7 | 8.5 | 2.4 | 94.4 | 213.4 | 237.0 | |
| Shareholders' equity | -31.3 | 272.9 | 230.8 | 256.8 | 114.3 | 12.5 |
USD millions · SEC XBRL
ARS Pharmaceuticals, Inc. — questions
- How much cash does ARS Pharmaceuticals, Inc. have?
- $8.2M in cash and cash equivalents as of 2026-06-30.
- How much debt does ARS Pharmaceuticals, Inc. have?
- $96.7M of long-term debt as of 2026-06-30.
- What are ARS Pharmaceuticals, Inc.'s total assets?
- $249.5M as of 2026-06-30.
- What is ARS Pharmaceuticals, Inc.'s shareholders' equity?
- $12.5M as of 2026-06-30.
Every figure on this page comes from ARS Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.